Chemotherapy-Induced Peripheral NeuropathyEPOOzo-2NCT07325851
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029.
An observational study of Chemotherapy-Induced Peripheral Neuropathy and Radiation Toxicity, run by Bernardino Clavo, MD, PhD at 1 site in Spain.
Trial summary
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity, Chronic Pain
- What is being tested?
- Ozone Therapy
- Type of treatment
- Surgery or procedure
- How many people
- 120 participants
- Where
- 1 siteSpain
- Study dates
- 14 Jan 2026to 30 Jun 2030
- How long will I take part?
- 40 Weeks
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín, between January 2026 and December 2029, for symptomatic/palliative treatment with ozone therapy because standard treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.
Who may be able to join
- 1. Adults ≥ 18 years old.
- 2. Patients referred to the Chronic Pain Unit of the Dr. Negrín University Hospital for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, has failed, has offered insufficient results, or is associated with high risk/morbidity.
- 3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.
- 4. Patients have no contraindications for ozone treatment.
- 5. Patients must sign the specific Informed Consent for this study and for the ozone treatment.
Who cannot join
- 1. Age < 18 years old.
- 2. Psychiatric illness or social situations that would limit compliance with study requirements.
- Contraindication or disability to attend scheduled treatments.
- 3. Contraindication or disability to attend scheduled treatments.
- 4. Uncontrolled clinical conditions (e.g., severe heart failure, massive hemorrhage, status epilepticus).
- 5. Life expectancy < 6 months.
Show all 11Show fewer
- 6. Known allergy to ozone.
- 7. Hemochromatosis (for systemic ozone treatment).
- 8. Pregnancy (for systemic ozone treatment).
- 9. Significant Glucose-6-Phosphate Dehydrogenase deficiency (Favism) (for systemic ozone treatment).
- 10. Patients who do not meet the inclusion criteria.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Dr. Negrín University Hospital
Las Palmas de Gran Canaria, Las Palmas, 35019
Bernardino Clavo, MD, PhD, +34 928449278, bernardinoclavo@gmail.com
Francisco Rodríguez-Esparragón, BSc, PhyD, +34 928449288, afrodesp@gmail.com
About this study
Official title: Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029. Prospective Study EPOOzo-2.
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Additionally, the study aims to evaluate several specific symptoms, hyperspectral and thermal images, non-invasive clinical parameters related to the Autonomic Nervous System (such as heart rate variability, electrochemical skin conductance, and vibration perception thresholds), oxidative stress and inflammatory parameters, and gut microbiota composition.
Read the detailed description
Patients are referred to the Chronic Pain Unit in the absence or failure of standard treatment, or when the standard treatment is associated with high morbidity or high risk. Frequently, these patients present alterations in self-perceived health-related quality of life (HRQoL), anxiety, depression, and other symptoms such as radiation-induced pelvic toxicity or chemotherapy-induced peripheral neuropathy (CIPN).
This prospective observational study (EPOOzo-2) aims to evaluate the effect of adjuvant symptomatic/palliative ozone therapy on HRQoL and potential changes from baseline. Specifically, it incorporates new non-invasive technologies to objectively assess microcirculation, neuropathy and autonomic regulation.
Main Objectives:
- Analyze the impact on HRQoL of patients with refractory symptoms treated with ozone.
Secondary Objectives: Depending on the clinical case, analyze the impact of ozone treatment on: 2. Anxiety and depression. 3. Treated symptoms (e.g., pain, paresthesia). 4. Fatigue. 5. Toxicity grade (in cancer patients). 6. Non-invasive clinical parameters related to the Autonomic Nervous System (central and peripheral) and somatosensory function. 7. Biochemical parameters and gut microbiome analysis (in patients with systemic/rectal ozone).
Methodology: Prospective and observational study of patients referred for symptomatic/palliative ozone therapy between January 2026 and December 2029.
Assessments at weeks: 0 (baseline), 16 (end of O3/O2 treatment), 28 (12 weeks after the end of ozone), and 40 (24 weeks after the end of ozone).
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity, Chronic Pain, Delayed Wound Healing, Refractory Symptoms
- Being tested
- Ozone Therapy
- Keywords
- Ozone Therapy, Health-related quality of life, Chemotherapy-induced Peripheral Neuropathy, Radiation-induced toxicity, Hyperspectral imaging, Infrared imaging, Heart Rate Variability, Sudoscan, Vibrometry, Oxidative stress, Gut Microbiota, Anxiety and Depression
- Medical subject headings
- Radiation Injuries, Chronic Pain, Anxiety Disorders, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ozone TherapyProcedure or surgery
Also called Ozone Treatment
Systemic (rectal, autohemotherapy) and/or local ozone administration (cutaneous, intravaginal, intravesical). Dosage, frequency, and duration will depend on the symptoms treated and clinical evolution. Usually planned 40 sessions over 4 months.
| Study group | Role | What they receive |
|---|---|---|
| Ozone Group | Patients with refractory symptoms referred for palliative treatment with ozone therapy between 2026 and 2029. Receives: Procedure: Ozone Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at the end of ozone therapy).
Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).
Measured: At the end of ozone therapy (approx. week 16).
Secondary outcomes (31)
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 12 weeks after the end of ozone therapy).
Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 24 weeks after the end of ozone therapy).
Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).
Measured: At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at the end of ozone therapy).
Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 12 weeks after the end of ozone therapy).
Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.
Measured: At 12 week after the end of ozone therapy (approx. week 28).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 24 weeks after the end of ozone therapy).
Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.
Measured: At 24 week after the end of ozone therapy (approx. week 40).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At the end of ozone therapy).
The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 12 weeks after the end of ozone therapy).
The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 24 weeks after the end of ozone therapy).
The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems
Measured: At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at the end of ozone therapy).
Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 12 weeks after the end of ozone therapy).
Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 24 weeks after the end of ozone therapy).
Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue
Measured: At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Pain Score (Visual Analog Scale), (at the end of ozone therapy).
Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Pain Score (Visual Analog Scale), (at 12 weeks after the end of ozone therapy).
Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Pain Score (Visual Analog Scale), (at 24 weeks after the end of ozone therapy).
Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").
Measured: At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at the end of ozone therapy).
Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 12 weeks after the end of ozone therapy).
Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 24 weeks after the end of ozone therapy).
Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).
Measured: At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at the end of ozone therapy).
Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at 12 weeks after the end of ozone therapy).
Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at the end of ozone therapy).
Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at 12 weeks after the end of ozone therapy).
Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Postural Stability (Equilibrium Platform), (at the end of ozone therapy).
Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Postural Stability (Equilibrium Platform), (at 12 weeks after the end of ozone therapy).
Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Heart Rate Variability (HRV), (at the end of ozone therapy).
Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Heart Rate Variability (HRV), (at 12 weeks after the end of ozone therapy).
Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at the end of ozone therapy).
Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.
Measured: At the end of ozone therapy (approx. week 16).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at 12 weeks after the end of ozone therapy).
Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at the end of ozone therapy).
Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.
Measured: At the end of ozone therapy (approx. week 16).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at 12 weeks after the end of ozone therapy).
Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Gut Microbiota Composition (at the end of ozone therapy).
Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).
Measured: At the end of ozone therapy (approx. week 16).
Change from Baseline in Gut Microbiota Composition (at 12 weeks after the end of ozone therapy).
Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).
Measured: At 12 weeks after the end of ozone therapy (approx. week 28).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2026
- Study start14 Jan 2026
- Primary completion31 Dec 2029 (estimated)
- Study completion30 Jun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for Chemotherapy-Induced Peripheral NeuropathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
- Target duration
- 40 Weeks
Sponsor and investigators
- Lead sponsor
- Bernardino Clavo, MD, PhD
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Universitario de Gran Canaria Doctor Negrín, Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Complejo Hospitalario Universitario Insular Materno Infantil, University of Las Palmas de Gran Canaria, Council of Gran Canaria
- Responsible party
- Sponsor-investigator, Bernardino Clavo, MD, PhD, Hospital Universitario de Gran Canaria Doctor Negrín
- Investigators
- Bernardino Clavo, MD, PhD, Study chair, Dr. Negrín University Hospital, Las Palmas, SpainFrancisco Rodríguez-Esparragón, BSc, PhyD, Principal investigator, Dr. Negrín University Hospital, Las Palmas, SpainÁngeles Cánovas-Molina, RN, Principal investigator, Dr. Negrín University Hospital, Las Palmas, Spain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07325851
- Sponsor's protocol ID
- 2025-642-1
- Other IDs
- 0177-2025-OBS
- Acronym
- EPOOzo-2
- Status last verified
- Sep 2026
- First submitted
- 23 Dec 2025
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: * It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification * Data will be available after publication, ending 36 months following the article publication. * They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose
Publications
Clavo B, Cordoba-Lanus E, Martinez-Sanchez G, Federico M, Canovas-Molina A, Pinero JE, Vargas-Prado AM, Ramchandani A, Zajac M, Ribeiro I, Navarro M, Jorge IJ, Gonzalez-Martin JM, Martin-Alfaro R, Fernandez-Tagarro M, Diaz-Garrido JA, Lorenzo-Morales J, Rodriguez-Esparragon F. Modulating the Gut Microbiota via Rectal Ozone Insufflation in Gynecological Cancer Patients with Radiotherapy/Chemotherapy-Induced Pelvic Toxicity: A Proposed Clinical Study Protocol. J Clin Med. 2025 Nov 12;14(22):8015. doi: 10.3390/jcm14228015.
PubMed 41303051Clavo B, Canovas-Molina A, Federico M, Martinez-Sanchez G, Benitez G, Galvan S, Ramallo-Farina Y, Fabelo H, Cazorla-Rivero S, Lago-Moreno E, Antonilli C, Diaz-Garrido JA, Jorge IJ, Marrero-Callico G, Rodriguez-Abreu D, Rodriguez-Esparragon F. Ozone Treatment in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Review of Rationale and Research Directions. Cancers (Basel). 2025 Jul 8;17(14):2278. doi: 10.3390/cancers17142278.
PubMed 40723162Bisshopp S, Linertova R, Carames MA, Szolna A, Jorge IJ, Navarro M, Melchiorsen B, Rodriguez-Diaz B, Gonzalez-Martin JM, Clavo B. Pain Relief, Disability, and Hospital Costs After Intradiscal Ozone Treatment or Microdiscectomy for Lumbar Disc Herniation: A 24-Month Real-World Prospective Study. J Clin Med. 2025 Jun 26;14(13):4534. doi: 10.3390/jcm14134534.
PubMed 40648907Clavo B, Canovas-Molina A, Garcia-Lourve C, Cazorla-Rivero S, Federico M, Rodriguez-Esparragon F. Effects of ozone treatment on chemotherapy-induced peripheral neuropathy: a promising research area. Med Gas Res. 2025 Jun 1;15(2):195-197. doi: 10.4103/mgr.MEDGASRES-D-24-00074. Epub 2025 Jan 18. No abstract available.
PubMed 40070187Clavo B, Rodriguez-Abreu D, Galvan-Ruiz S, Federico M, Canovas-Molina A, Ramallo-Farina Y, Antonilli C, Benitez G, Fabelo H, Garcia-Lourve C, Gonzalez-Beltran D, Jorge IJ, Rodriguez-Esparragon F, Callico GM. Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study. Integr Cancer Ther. 2025 Jan-Dec;24:15347354241307038. doi: 10.1177/15347354241307038.
PubMed 39797612Clavo B, Canovas-Molina A, Diaz-Garrido JA, Canas S, Ramallo-Farina Y, Laffite H, Federico M, Rodriguez-Abreu D, Galvan S, Garcia-Lourve C, Gonzalez-Beltran D, Carames MA, Hernandez-Fleta JL, Serrano-Aguilar P, Rodriguez-Esparragon F. Effects of ozone therapy on anxiety and depression in patients with refractory symptoms of severe diseases: a pilot study. Front Psychol. 2023 Aug 4;14:1176204. doi: 10.3389/fpsyg.2023.1176204. eCollection 2023.
PubMed 37599784Clavo B, Rodriguez-Abreu D, Galvan S, Federico M, Martinez-Sanchez G, Ramallo-Farina Y, Antonelli C, Benitez G, Rey-Baltar D, Jorge IJ, Rodriguez-Esparragon F, Serrano-Aguilar P. Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report. Front Physiol. 2022 Aug 30;13:935269. doi: 10.3389/fphys.2022.935269. eCollection 2022.
PubMed 36111149Clavo B, Canovas-Molina A, Ramallo-Farina Y, Federico M, Rodriguez-Abreu D, Galvan S, Ribeiro I, Marques da Silva SC, Navarro M, Gonzalez-Beltran D, Diaz-Garrido JA, Cazorla-Rivero S, Rodriguez-Esparragon F, Serrano-Aguilar P. Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors. Int J Environ Res Public Health. 2023 Jan 13;20(2):1479. doi: 10.3390/ijerph20021479.
PubMed 36674232Clavo B, Gutierrez D, Martin D, Suarez G, Hernandez MA, Robaina F. Intravesical ozone therapy for progressive radiation-induced hematuria. J Altern Complement Med. 2005 Jun;11(3):539-41. doi: 10.1089/acm.2005.11.539.
PubMed 15992242Clavo B, Suarez G, Aguilar Y, Gutierrez D, Ponce P, Cubero A, Robaina F, Carreras JL. Brain ischemia and hypometabolism treated by ozone therapy. Forsch Komplementmed. 2011;18(5):283-7. doi: 10.1159/000333795. Epub 2011 Oct 13.
PubMed 22105041Clavo B, Ceballos D, Gutierrez D, Rovira G, Suarez G, Lopez L, Pinar B, Cabezon A, Morales V, Oliva E, Fiuza D, Santana-Rodriguez N. Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy. J Pain Symptom Manage. 2013 Jul;46(1):106-12. doi: 10.1016/j.jpainsymman.2012.06.017. Epub 2012 Oct 26.
PubMed 23102757Clavo B, Santana-Rodriguez N, Gutierrez D, Lopez JC, Suarez G, Lopez L, Robaina F, Bocci V. Long-term improvement in refractory headache following ozone therapy. J Altern Complement Med. 2013 May;19(5):453-8. doi: 10.1089/acm.2012.0273. Epub 2012 Dec 7.
PubMed 23215625Clavo B, Santana-Rodriguez N, Llontop P, Gutierrez D, Ceballos D, Mendez C, Rovira G, Suarez G, Rey-Baltar D, Garcia-Cabrera L, Martinez-Sanchez G, Fiuza D. Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients. Evid Based Complement Alternat Med. 2015;2015:480369. doi: 10.1155/2015/480369. Epub 2015 Aug 18.
PubMed 26357522Clavo B, Santana-Rodriguez N, Llontop P, Gutierrez D, Suarez G, Lopez L, Rovira G, Martinez-Sanchez G, Gonzalez E, Jorge IJ, Perera C, Blanco J, Rodriguez-Esparragon F. Ozone Therapy as Adjuvant for Cancer Treatment: Is Further Research Warranted? Evid Based Complement Alternat Med. 2018 Sep 9;2018:7931849. doi: 10.1155/2018/7931849. eCollection 2018.
PubMed 30271455Clavo B, Rodriguez-Esparragon F, Rodriguez-Abreu D, Martinez-Sanchez G, Llontop P, Aguiar-Bujanda D, Fernandez-Perez L, Santana-Rodriguez N. Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects. Antioxidants (Basel). 2019 Nov 26;8(12):588. doi: 10.3390/antiox8120588.
PubMed 31779159